SomaLogic (SomaLogic) ROCE % : -17.54% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SomaLogic ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SomaLogic's annualized ROCE % for the quarter that ended in Sep. 2023 was -17.54%.

SomaLogic ROCE % Historical Data

The historical data trend for SomaLogic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic ROCE % Chart

SomaLogic Annual Data

Trend

Dec20

Dec21

Dec22

ROCE %

-15.45

-19.12

-17.16

SomaLogic Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial								-23.99	5.48	-27.26	-22.02	-17.54

SomaLogic ROCE % Calculation

SomaLogic's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-109.874	/	( ( (706.102 - 29.285)	+	(647.374 - 43.332) )	/ 2 )
	=	-109.874	/	( (676.817	+	604.042)	/ 2 )
	=	-109.874	/	640.4295
	=	-17.16 %

SomaLogic's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-95.7	/	( ( (585.746 - 31.501)	+	(565.048 - 27.781) )	/ 2 )
	=	-95.7	/	( ( 554.245	+	537.267 )	/ 2 )
	=	-95.7	/	545.756
	=	-17.54 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

SomaLogic (NAS:SLGC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SomaLogic ROCE % Related Terms

Thank you for viewing the detailed overview of SomaLogic's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SomaLogic (SomaLogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2945 Wilderness Place, Boulder, CO, USA, 80301

Website

https://www.somalogic.com

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Executives

Alison Marie Roelke	officer: Chief People Officer	900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich	officer: Interim CEO	C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez	officer: General Counsel	6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs	director	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey	director	8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman	officer: Chief Financial Officer	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post	director	998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis	director	13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake	director	C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi	director